EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov Phase 1 solid tumors

EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov

Official Title:

EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial

This study is not yet open for participant recruitment.

Verified May 2012 by M.D. Anderson Cancer Center

First Received on May 2, 2012.   No Changes Posted

Sponsor:	M.D. Anderson Cancer Center
Collaborator:	Ovarian Cancer Research Fund
Information provided by (Responsible Party):	M.D. Anderson Cancer Center ( M.D. Anderson Cancer Center )
ClinicalTrials.gov Identifier:	NCT01591356

  Purpose

The goal of this clinical research study is to learn about the safety of siRNA-EphA2-DOPC when given to patients with advanced, recurrent cancer. Researchers also want to learn the highest tolerable dose of this drug that can be given.

siRNA-EphA2-DOPC is designed to shut down the activity of a gene that causes tumor growth.